Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2005

01-07-2005 | Review

Vitamin D and diabetes

Authors: C. Mathieu, C. Gysemans, A. Giulietti, R. Bouillon

Published in: Diabetologia | Issue 7/2005

Login to get access

Abstract

Vitamin D deficiency predisposes individuals to type 1 and type 2 diabetes, and receptors for its activated form—1α,25-dihydroxyvitamin D3—have been identified in both beta cells and immune cells. Vitamin D deficiency has been shown to impair insulin synthesis and secretion in humans and in animal models of diabetes, suggesting a role in the development of type 2 diabetes. Furthermore, epidemiological studies suggest a link between vitamin D deficiency in early life and the later onset of type 1 diabetes. In some populations, type 1 diabetes is associated with certain polymorphisms within the vitamin D receptor gene. In studies in nonobese diabetic mice, pharmacological doses of 1α,25-dihydroxyvitamin D3, or its structural analogues, have been shown to delay the onset of diabetes, mainly through immune modulation. Vitamin D deficiency may, therefore, be involved in the pathogenesis of both forms of diabetes, and a better understanding of the mechanisms involved could lead to the development of preventive strategies.
Literature
1.
2.
Haussler MR, Whitfield GK, Haussler CA et al (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349PubMed
3.
Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ (1995) Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 38:1239–1245CrossRefPubMed
4.
Isaia G, Giorgino R, Adami S (2001) High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 24:1496
5.
Chiu KC, Chu A, Go VL, Saad MF (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79:820–825PubMed
6.
Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R (1994) Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 37:552–558PubMed
7.
D’Ambrosio D, Cippitelli M, Cocciolo MG et al (1998) Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 101:252–262PubMed
8.
van Halteren AG, Van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C (2002) Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D3. Diabetes 51:2119–2125PubMed
9.
Bouillon R, Verstuyf A, Verlinden L, Eelen G, Mathieu C (2003) Prospects for vitamin D receptor modulators as candidate drugs for cancer and (auto)immune diseases. Recent Results Cancer Res 164:353–356PubMed
10.
Bouillon R, Garmyn M, Verstuyf A, Segaert S, Casteels K, Mathieu C (1995) Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analogs. Eur J Endocrinol 133:7–16PubMed
11.
Rajakumar K (2003) Vitamin D, cod-liver oil, sunlight, and rickets: a historical perspective. Pediatrics 112:e132–e135CrossRefPubMed
12.
Windaus A, Linsert O, Luttringhaus A, Weidlinch G (1932) Uber das krystallistierte Vitamin D2. Justus Liebigs Ann Chem 492:226–231
13.
Holick MF, Clark MB (1978) The photobiogenesis and metabolism of vitamin D. Fed Proc 37:2567–2574PubMed
14.
Inouye K, Sakaki T (2001) Enzymatic studies on the key enzymes of vitamin D metabolism: 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol Annu Rev 7:179–194CrossRefPubMed
15.
Fu GK, Lin D, Zhang MY et al (1997) Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 11:1961–1970CrossRefPubMed
16.
Hewison M, Freeman L, Hughes SV et al (2003) Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol 170:5382–5390PubMed
17.
Overbergh L, Decallonne B, Valckx D et al (2000) Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 120:139–146CrossRefPubMed
18.
Tanaka Y, Castillo L, Deluca HF (1977) The 24-hydroxylation of 1,25-dihydroxyvitamin D3. J Biol Chem 252:1421–1424
19.
Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J (1993) Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest 91:2552–2555PubMed
20.
Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D (2000) The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 5:173–179CrossRefPubMed
21.
Vidal M, Ramana CV, Dusso AS (2002) Stat1–vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol 22:2777–2787CrossRefPubMed
22.
Christakos S, Barletta F, Huening M et al (2003) Vitamin D target proteins: function and regulation. J Cell Biochem 88:238–244CrossRefPubMed
23.
Maestro B, Davila N, Carranza MC, Calle C (2003) Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 84:223–230CrossRefPubMed
24.
Eerligh P, Koeleman BP, Dudbridge F, Jan BG, Roep BO, Giphart MJ (2004) Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes. Genes Immun 5:36–40CrossRefPubMed
25.
Verstuyf A, Verlinden L, van Baelen H et al (1998) The biological activity of nonsteroidal vitamin D hormone analogs lacking both the C- and D-rings. J Bone Miner Res 13:549–558PubMed
26.
Verstuyf A, Verlinden L, Van Etten E et al (2000) Biological activity of CD-ring modified 1alpha,25-dihydroxyvitamin D analogues: C-ring and five-membered D-ring analogues. J Bone Miner Res 15:237–252PubMed
27.
De Clercq PJ, Murad I, Gao LJ et al (2004) Biological activity and conformational analysis of C20 and C14 epimers of CD-ring modified trans-decalin 1alpha,25-dihydroxyvitamin D analogs. J Steroid Biochem Mol Biol 89–90:61–66CrossRefPubMed
28.
Gedik O, Akalin S (1986) Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia 29:142–145PubMed
29.
Norman AW, Frankel JB, Heldt AM, Grodsky GM (1980) Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209:823–825PubMed
30.
Lee S, Clark SA, Gill RK, Christakos S (1994) 1,25-Dihydroxyvitamin D3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology 134:1602–1610CrossRefPubMed
31.
Sooy K, Schermerhorn T, Noda M et al (1999) Calbindin-D(28k) controls [Ca(2+)](i) and insulin release. Evidence obtained from calbindin-D(28k) knockout mice and beta cell lines. J Biol Chem 274:34343–34349
32.
Rabinovitch A, Suarez-Pinzon WL, Sooy K, Strynadka K, Christakos S (2001) Expression of calbindin-D(28k) in a pancreatic islet beta-cell line protects against cytokine-induced apoptosis and necrosis. Endocrinology 142:3649–3655CrossRefPubMed
33.
Hitman GA, Mannan N, McDermott MF et al (1998) Vitamin D receptor gene polymorphisms influence insulin secretion in Bangladeshi Asians. Diabetes 47:688–690PubMed
34.
Oh JY, Barrett-Connor E (2002) Association between vitamin D receptor polymorphism and type 2 diabetes or metabolic syndrome in community-dwelling older adults: the Rancho Bernardo Study. Metabolism 51:356–359CrossRefPubMed
35.
Ortlepp JR, Metrikat J, Albrecht M, von Korff A, Hanrath P, Hoffmann R (2003) The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. Diabet Med 20:451–454CrossRefPubMed
36.
Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF (1983) Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 113:1511–1518PubMed
37.
Cade C, Norman AW (1986) Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 119:84–90PubMed
38.
Kadowaki S, Norman AW (1984) Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest 73:759–766PubMed
39.
Nyomba BL, Bouillon R, De Moor P (1984) Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology 115:191–197PubMed
40.
Tanaka Y, Seino Y, Ishida M et al (1984) Effect of vitamin D3 on the pancreatic secretion of insulin and somatostatin. Acta Endocrinol (Copenh) 105:528–533
41.
Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG (2003) Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 17:509–511PubMed
42.
Mathieu C, Van Etten E, Gysemans C et al (2001) In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J Bone Miner Res 16:2057–2065PubMed
43.
d’Emden MC, Dunlop M, Larkins RG, Wark JD (1989) The in vitro effect of 1 alpha,25-dihydroxyvitamin D3 on insulin production by neonatal rat islets. Biochem Biophys Res Commun 164:413–418PubMed
44.
de Boland AR, Norman AW (1990) Influx of extracellular calcium mediates 1,25-dihydroxyvitamin D3-dependent transcaltachia (the rapid stimulation of duodenal Ca2+ transport). Endocrinology 127:2475–2480PubMed
45.
Billaudel BJ, Faure AG, Sutter BC (1990) Effect of 1,25 dihydroxyvitamin D3 on isolated islets from vitamin D3-deprived rats. Am J Physiol 258:E643–E648PubMed
46.
Bourlon PM, Faure-Dussert A, Billaudel B (1997) Modulatory role of 1,25 dihydroxyvitamin D3 on pancreatic islet insulin release via the cyclic AMP pathway in the rat. Br J Pharmacol 121:751–758
47.
Kumar S, Davies M, Zakaria Y et al (1994) Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 70:440–443PubMed
48.
Allegra V, Luisetto G, Mengozzi G, Martimbianco L, Vasile A (1994) Glucose-induced insulin secretion in uremia: role of 1 alpha,25(OH)2-vitamin D3. Nephron 68:41–47PubMed
49.
Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R (2003) The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 57:258–261
50.
Taylor AV, Wise PH (1998) Vitamin D replacement in Asians with diabetes may increase insulin resistance. Postgrad Med J 74:365–366PubMed
51.
Karvonen M, Jantti V, Muntoni S et al (1998) Comparison of the seasonal pattern in the clinical onset of IDDM in Finland and Sardinia. Diabetes Care 21:1101–1109PubMed
52.
Stene LC, Joner G (2003) Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 78:1128–1134PubMed
53.
The EURODIAB Substudy 2 Study Group (1999) Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus. Diabetologia 42:51–54
54.
Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM (2001) Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358:1500–1503PubMed
55.
Fronczak CM, Baron AE, Chase HP et al (2003) In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care 26:3237–3242PubMed
56.
Mathieu C, Van Etten E, Gysemans C, Decallonne B, Bouillon R (2002) Seasonality of birth in patients with type 1 diabetes. Lancet 359:1248CrossRef
57.
Mathieu C, Van Etten E, Decallonne B et al (2004) Vitamin D and 1,25-dihydroxyvitamin D(3) as modulators in the immune system. J Steroid Biochem Mol Biol 89–90:449–452PubMed
58.
Giulietti A, Gysemans C, Stoffels K et al (2004) Vitamin D deficiency in early life accelerates type 1 diabetes in non-obese diabetic mice. Diabetologia 47:451–462PubMed
59.
Zella JB, McCary LC, Deluca HF (2003) Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys 417:77–80PubMed
60.
McDermott MF, Ramachandran A, Ogunkolade BW et al (1997) Allelic variation in the vitamin D receptor influences susceptibility to IDDM in Indian Asians. Diabetologia 40:971–975PubMed
61.
Pani MA, Knapp M, Donner H et al (2000) Vitamin D receptor allele combinations influence genetic susceptibility to type 1 diabetes in Germans. Diabetes 49:504–507PubMed
62.
Ban Y, Taniyama M, Yanagawa T et al (2001) Vitamin D receptor initiation codon polymorphism influences genetic susceptibility to type 1 diabetes mellitus in the Japanese population. BMC Med Genet 2:7PubMed
63.
Ogunkolade BW, Boucher BJ, Prahl JM et al (2002) Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 51:2294–2300PubMed
64.
Yokota I, Satomura S, Kitamura S et al (2002) Association between vitamin D receptor genotype and age of onset in juvenile Japanese patients with type 1 diabetes. Diabetes Care 25:1244
65.
Motohashi Y, Yamada S, Yanagawa T et al (2003) Vitamin D receptor gene polymorphism affects onset pattern of type 1 diabetes. J Clin Endocrinol Metab 88:3137–3140PubMed
66.
Nejentsev S, Cooper JD, Godfrey L et al (2004) Analysis of the vitamin D receptor gene sequence variants in type 1 diabetes. Diabetes 53:2709–2712PubMed
67.
Mathieu C, Adorini L (2002) The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 8:174–179PubMed
68.
Adams JS, Sharma OP, Gacad MA, Singer FR (1983) Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 72:1856–1860PubMed
69.
Adorini L (2003) Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci 987:258–261PubMed
70.
Adorini L, Penna G, Giarratana N et al (2004) Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J Steroid Biochem Mol Biol 89–90:437–441PubMed
71.
Van Etten E, Decallonne B, Bouillon R, Mathieu C (2004) NOD bone marrow-derived dendritic cells are modulated by analogs of 1,25-dihydroxyvitamin D(3). J Steroid Biochem Mol Biol 89–90:457–459PubMed
72.
Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R (2000) Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 270:701–708
73.
Penna G, Adorini L (2000) 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164:2405–2411PubMed
74.
Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R (2001) Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 98:6800–6805PubMed
75.
Overbergh L, Decallonne B, Waer M et al (2000) 1alpha,25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes 49:1301–1307PubMed
76.
Boonstra A, Barrat FJ, Crain C, Health VL, Savelkoul HF, O’Garra A (2001) 1alpha,25-dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167:4974–4980PubMed
77.
Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L (2002) A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 51:1367–1374PubMed
78.
Towers TL, Staeva TP, Freedman LP (1999) A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Mol Cell Biol 19:4191–4199PubMed
79.
Takeuchi A, Reddy GS, Kobayashi T, Okano T, Park J, Sharma S (1998) Nuclear factor of activated T cells (NFAT) as a molecular target for 1alpha,25-dihydroxyvitamin D3-mediated effects. J Immunol 160:209–218PubMed
80.
Reichel H, Koeffler HP, Tobler A, Norman AW (1987) 1 alpha,25-dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 84:3385–3389PubMed
81.
Cippitelli M, Santoni A (1998) Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 28:3017–3030PubMed
82.
Sandler S, Buschard K, Bendtzen K (1994) Effects of 1,25-dihydroxyvitamin D3 and the analogues MC903 and KH1060 on interleukin-1 beta-induced inhibition of rat pancreatic islet beta-cell function in vitro. Immunol Lett 41:73–77PubMed
83.
Hahn HJ, Kuttler B, Mathieu C, Bouillon R (1997) 1,25-Dihydroxyvitamin D3 reduces MHC antigen expression on pancreatic beta-cells in vitro. Transplant Proc 29:2156–2157PubMed
84.
Mauricio D, Andersen H, Karlsen A, Mandrup-Poulsen T, Nerup J (1995) Effect of steroidal hormones on interleukin-1beta action on rat islets. Diabetologia 38S:A80
85.
Riachy R, Vandewalle B, Belaich S et al (2001) Beneficial effect of 1,25 dihydroxyvitamin D3 on cytokine-treated human pancreatic islets. J Endocrinol 169:161–168PubMed
86.
Riachy R, Vandewalle B, Kerr CJ et al (2002) 1,25-dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20. Endocrinology 143:4809–4819PubMed
87.
Gysemans CA, Cardozo AK, Callewaert H et al (2005) 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 146:1956–1964PubMed
88.
Mathieu C, Laureys J, Sobis H, Vandeputte M, Waer M, Bouillon R (1992) 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes 41:1491–1495PubMed
89.
Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R (1995) Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 136:866–872PubMed
90.
Casteels K, Waer M, Bouillon R et al (1998) 1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clin Exp Immunol 112:181–187PubMed
91.
van Halteren AG, Tysma OM, van Etten E, Mathieu C, Roep BO (2004) 1alpha,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 23:233–239PubMed
92.
Casteels KM, Gysemans CA, Waer M et al (1998) Sex difference in resistance to dexamethasone-induced apoptosis in NOD mice: treatment with 1,25(OH)2D3 restores defect. Diabetes 47:1033–1037PubMed
93.
Mathieu C, Casteels K, Bouillon R (1997) Vitamin D and diabetes. In: Feldman D, Glorieux F, Pike J (eds) Vitamin D. Academic, San Diego, pp 1183–1196
94.
Bach JF (1994) Predictive medicine in autoimmune diseases: from the identification of genetic predisposition and environmental influence to precocious immunotherapy. Clin Immunol Immunopathol 72:156–161PubMed
95.
Casteels K, Waer M, Bouillon R, Allewaert K, Laureys J, Mathieu C (1996) Prevention of type I diabetes by late intervention with nonhypercalcemic analogues of vitamin D3 in combination with cyclosporin A. Transplant Proc 28:3095PubMed
96.
Mathieu C, Laureys J, Waer M, Bouillon R (1994) Prevention of autoimmune destruction of transplanted islets in spontaneously diabetic NOD mice by KH1060, a 20-epi analog of vitamin D: synergy with cyclosporine. Transplant Proc 26:3128–3129PubMed
97.
Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L (2001) Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 167:1945–1953PubMed
98.
Gysemans C, Van Etten E, Overbergh L et al (2002) Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin-D3. Clin Exp Immunol 128:213–220PubMed
99.
Orwoll E, Riddle M, Prince M (1994) Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr 59:1083–1087PubMed
Metadata
Title
Vitamin D and diabetes
Authors
C. Mathieu
C. Gysemans
A. Giulietti
R. Bouillon
Publication date
01-07-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1802-7

Other articles of this Issue 7/2005

Diabetologia 7/2005 Go to the issue

Article

Diabetes in rat pregnancy alters renal calcium and magnesium reabsorption and bone formation in adult offspring

Letter

Reply to Comment on: Mackin P, Watkinson HM, Young AH (2005) Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48:215–221

Article

Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study

Article

Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men

Article

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

Article

Single nucleotide polymorphisms in the gene encoding Krüppel-like factor 7 are associated with type 2 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits